Skip to content
Review Open access

A Data-Driven Atlas of CAR-Based Immunotherapy in Lung Cancer: Insights from Multidatabase Integration.

Aug 2026 · Pharmacological Research · Vol 231, pp. 108368 · 0 citations · 145 references
Medicine

TL;DR

A data-driven pharmacological atlas of CAR-based immunotherapy in lung cancer is furnished, illuminating key therapeutic targets, evolving treatment paradigms, and prospective opportunities for clinical translation.

Abstract

Lung cancer remains a leading cause of cancer-related mortality worldwide, and the clinical translation of chimeric antigen receptor (CAR)-based immunotherapy into solid tumors continues to be constrained by antigen heterogeneity, an immunosuppressive microenvironment, and stromal barriers that impede immune cell trafficking and curtail efficacy. Here, we present a comprehensive bibliometric analysis of CAR-based immunotherapy for lung cancer, drawing on publications indexed in the Web of Science Core Collection and Scopus between 2016 and 2025. Bibliometric and network analyses elucidate global research trajectories, collaboration patterns, and emergent therapeutic themes, while clinical trial data from ClinicalTrials.gov further appraise translational progress. This landscape has expanded rapidly, with growing emphasis on CAR engineering, microenvironment modulation, precision targeting, and combinatorial strategies. Clinical evidence, though drawn from a still-limited number of trials, indicates generally tolerable toxicity in most reported cases; nevertheless, severe and occasionally fatal adverse events have been documented, underscoring the need for continued vigilance in safety evaluation. Antitumor efficacy remains modest, reflecting persistent challenges in target selection, tumor accessibility, cellular persistence, and functional maintenance. Emerging strategies, including multi-target CAR architectures, rational drug combinations, and biomarker-guided patient stratification, may offer avenues for overcoming these limitations. This study furnishes a data-driven pharmacological atlas of CAR-based immunotherapy in lung cancer, illuminating key therapeutic targets, evolving treatment paradigms, and prospective opportunities for clinical translation.

Read PDF

Similar papers

Review Sep 2026

Emerging Therapies in Lung Cancer: A Review on Targeted and Immune Based Interventions.

This review encapsulates significant developments in molecularly targeted agents and immune checkpoint inhibitors, emphasising their clinical efficacy, resistance mechanisms, and innovative therapeutic combinations, and reviews pivotal clinical trials and newly filed patents.

K. C. Geervani, R. Maddileti, Kalpi Sania Kausar et al. · 0 citations
Review Open access Sep 2026

Guiding the Application of Immunotherapy in Nonsmall Cell Lung Cancer: The Role of Biomarkers

Although immunotherapy has completely transformed the treatment landscape of nonsmall cell lung cancer (NSCLC), its wide application is still limited by the heterogeneity of patient responses, primary and acquired resistance, as well as the management challenges of immune‐related adverse events (irAEs). To achieve prec...

Yu-Ting Sun, Xue-Lei Chu, Xin-Miao Wang et al. · 0 citations
Open access Sep 2026

The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies

Background Non-small cell lung cancer (NSCLC) management remains constrained by acquired resistance to targeted therapies and refractoriness to immune checkpoint inhibitors (ICIs), the latter driven largely by the immunosuppressive tumor microenvironment (TME). Bispecific antibodies (bsAbs) represent a promising modali...

Zun-Yuan Li, Xi-Yu Wang, Qin Shi et al. · 0 citations
Review Open access Aug 2026

Building bridges to immunotherapy: a knowledge-mapping analysis of cervical cancer organoid research

The analysis suggests the role of organoids as a crucial bridge linking basic virology to clinical immuno-oncology, highlighting that current advancements in tumor microenvironment modeling are establishing the necessary foundation for future immunotherapeutic applications.

Yuan-Yuan Tian, Hui Chang, Jin-Jin Liu et al. · 0 citations
Review Oct 2026

γδ T Cells in Cancer Immunotherapy, 2000-2025: A Bibliometric Analysis and Clinical-Trial Evidence Map.

γδ T cells are promising cancer-immunotherapy effectors because they recognize tumors without major histocompatibility complex (MHC) restriction and carry low graft-versus-host-disease risk in allogeneic settings, yet few bibliometric studies have integrated immunotherapy-specific research trends with clinical-trial ma...

Yu-Heng Wang, Yuan-Zhi He, Jia-Yu Xu et al. · 0 citations
Review Open access Aug 2026

Molecular classification and precision therapy in gastric cancer: Current advances and future perspectives (Review)

Focusing on acquired resistance as a core bottleneck in precision therapy, mechanisms underlying anti-Human Epidermal Growth Factor Receptor 2 (HER2) resistance and primary/secondary resistance to immune checkpoint inhibitors (ICIs) were systematically dissected, while also addressing immune-related adverse events and...

Shu-Jing Xia, Xiumei Zhang, Li-Zhong Tang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.